Envue Medical, Inc. (FEED) Stock Price & Analysis
Envue Medical, Inc. (FEED) fell 0.57% to USD 0.38 as of July 25, 2026 at 04:54 UTC, according to Nexqual real-time market data.
FEED last closed at USD 0.38; the session ranged USD 0.37–0.38 on volume of 56,920 shares. Market capitalization is $2.33M, with a 52-week range of USD 0.35–17.4 (NCM). Source: Nexqual, July 25, 2026 at 04:54 UTC.
Key Statistics (as of July 25, 2026 at 04:54 UTC)
| Price | USD 0.38 |
|---|---|
| Change | ▼ 0.57% (down) |
| Previous Close | USD 0.38 |
| Open | USD 0.37 |
| Day Range | USD 0.37 – 0.38 |
| 52-Week Range | USD 0.35 – 17.4 |
| Volume | 56,920 shares |
| Market Cap | $2.33M |
| Exchange | NCM |
Technical Analysis (FEED)
Nexqual's technical model rates FEED "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.17 (oversold) |
| vs SMA50 | Below (USD 0.7) |
| MACD | -0.1 (negative) |
Analyst Ratings (FEED)
Wall Street analysts rate FEED "None", per Nexqual as of July 25, 2026 at 04:54 UTC.
| Consensus Rating | None |
|---|
Earnings (FEED)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2019-09-30 | USD -264 vs est -440 ▲ beat |
| 2019-06-30 | USD -352 vs est -440 ▲ beat |
| 2019-03-31 | USD -749.76 vs est -462 ▼ miss |
| 2018-12-31 | USD -396 vs est -286 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Financials & Fundamentals (FEED)
| Total Revenue | $2.18M |
|---|---|
| Revenue Growth (YoY) | -36.30% |
| Gross Margin | -12.43% |
| Operating Margin | -568.30% |
| Profit Margin | +0.00% |
| ROE | -59.49% |
| Debt / Equity | 3.78 |
| Current Ratio | 0.9 |
| Total Cash | $2.23M |
| Total Debt | $1.21M |
| Free Cash Flow | $-6.80M |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Financial Health Score (FEED)
Nexqual rates Envue Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:54 UTC.
| Growth | Strong — Revenue +33% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $2M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -59%, ROA -20.2% |
Ownership (FEED)
| Insider Ownership | +1.47% |
|---|---|
| Institutional Ownership | +1.04% |
| Shares Outstanding | 6.09M |
| Float | 6.09M |
| Short % of Float | +1.01% |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
Leadership (FEED)
Envue Medical, Inc. is led by Doron Robert Besser (age 56), CEO, President & Director, per Nexqual as of July 25, 2026 at 04:54 UTC.
| CEO, President & Director | Doron Robert Besser (age 56) |
|---|---|
| Interim Chief Financial Officer | Nicole Fernandez-McGovern (age 52) |
| Vice President of Sales | Lindsey Harrison |
Major Backers & Investors (FEED)
Notable institutional backers of Envue Medical, Inc. include Fidelity, Schonfeld Strategic Advisors Llc, Osaic Holdings Inc., according to Nexqual as of July 25, 2026 at 04:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.26% |
| Schonfeld Strategic Advisors Llc | 0.22% |
| Osaic Holdings Inc. | 0.16% |
| Morgan Stanley | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.37% |
Source: Nexqual, July 25, 2026 at 04:54 UTC.
From Envue Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance.
- Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
- The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures.
- In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| SEED | Origin Agritech Limited | USD 1.01 | ▲ 0% |
| WORX | SCWorx Corp. | USD 0.59 | ▲ 3.33% |
| ADTX | Aditxt, Inc. | USD 0 | ▲ 33.33% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:54 UTC. This page is informational and not investment advice.